Probing into the Biological Processes Influenced by ESC Factor and Oncoprotein HMGA2 Using iPSCs

Stem Cell Reviews and Reports

Volumn 9, Issue 4, 2013, Pages 514-522

  Morshedi, Amir ^a   Ren, Zhonglu ^b   Li, Jinming ^b   Dröge, Peter ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Diabetes; HMGA2; Human stature; Induced Pluripotent Stem Cells

Indexed keywords

MAMMALIA;

BIOLOGICAL MARKER; HIGH MOBILITY GROUP A2 PROTEIN; ONCOPROTEIN;

ANIMAL; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL LINE; CFU COUNTING; CYTOLOGY; DOWN REGULATION; EMBRYONIC STEM CELL; GENE ONTOLOGY; GENETICS; HUMAN; METABOLISM; MOUSE; PLURIPOTENT STEM CELL; REGULATOR GENE;

ANIMALS; BIOLOGICAL MARKERS; CELL COUNT; CELL DIFFERENTIATION; CELL LINE; COLONY-FORMING UNITS ASSAY; DOWN-REGULATION; EMBRYONIC STEM CELLS; GENE ONTOLOGY; GENES, REGULATOR; HMGA2 PROTEIN; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; ONCOGENE PROTEINS;

EID: 84881614423     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-012-9373-8     Document Type: Article

References (45)

1. Yamanaka, S. (2009). A fresh look at iPS cells. Cell, 137(1), 13-17.
2. Grskovic, M., Javaherian, A., Strulovici, B., & Daley, G. Q. (2011). Induced pluripotent stem cells-opportunities for disease modelling and drug discovery. Nature Reviews. Drug Discovery, 10(12), 915-929.
3. Wu, S. M., & Hochedlinger, K. (2011). Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nature Cell Biology, 13(5), 497-505.
4. Wilmut, I., Sullivan, G., & Chambers, I. (2011). The evolving biology of cell reprogramming. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 366(1575), 2183-2197.
5. Tiscornia, G., Vivas, E. L., & Belmonte, J. C. I. (2011). Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nature Medicine, 17(12), 1570-1576.
6. Caron, L., Bost, F., Prot, M., Hofman, P., & Binetruy, B. (2005). A new role for the oncogenic high-mobility group A2 transcription factor in myogenesis of embryonic stem cells. Oncogene, 24(41), 6281-6291.
7. Hirning-Folz, U., Wilda, M., Rippe, V., Bullerdiek, J., & Hameister, H. (1998). The expression pattern of the Hmgic gene during development. Genes, Chromosomes & Cancer, 23(4), 350-357.
8. Pfannkuche, K., Summer, H., Li, O., Hescheler, J., & Droge, P. (2009). The high mobility group protein HMGA2: A co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Reviews, 5(3), 224-230.
9. Huth, J. R., Bewley, C. A., Nissen, M. S., et al. (1997). The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif. Nature Structural & Molecular Biology, 4(8), 657-665.
10. Droge, P., & Davey, C. A. (2008). Do cells let-7 determine stemness? Cell Stem Cell, 2(1), 8-9.
11. Chiappetta, G., Ferraro, A., Vuttariello, E., et al. (2008). HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. European Journal of Cancer, 44(7), 1015-1021.
12. Fedele, M., Palmieri, D., & Fusco, A. (2010). HMGA2: A pituitary tumour subtype-specific oncogene? Molecular and Cellular Endocrinology, 326(1-2), 19-24.
13. Summer, H., Li, O., Bao, Q., et al. (2009). HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Research, 37(13), 4371-4384.
14. Cleynen, I., & van de Ven, W. J. (2008). The HMGA proteins: A myriad of functions (Review). International Journal of Oncology, 32(2), 289-305.
15. Li, A. Y., Lin, H. H., Kuo, C. Y., et al. (2011). High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Molecular and Cellular Biology, 31(13), 2605-2617.
16. Song, C., Gu, X., Feng, C., et al. (2011). Evaluation of SNPs in the chicken HMGA2 gene as markers for body weight gain. Animal Genetics, 42(3), 333-336.
17. Winkler, S., Escobar, H. M., Meyer, B., et al. (2007). HMGA2 expression in a canine model of prostate cancer. Cancer Genetics and Cytogenetics, 177(2), 98-102.
18. Weedon, M. N., Lettre, G., Freathy, R. M., et al. (2007). A common variant of HMGA2 is associated with adult and childhood height in the general population. Nature Genetics, 39(10), 1245-1250.
19. Battista, S., Fidanza, V., Fedele, M., et al. (1999). The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Research, 59(19), 4793-4797.
20. Sanna, S., Jackson, A. U., Nagaraja, R., et al. (2008). Common variants in the GDF5-UQCC region are associated with variation in human height. Nature Genetics, 40(2), 198-203.
21. Tay, Y., Peter, S., Rigoutsos, I., Barahona, P., Ahmed, S., & Droge, P. (2009). Insights into the regulation of a common variant of HMGA2 associated with human height during embryonic development. Stem Cell Reviews and Reports, 5(4), 328-333.
22. Tzatsos, A., & Bardeesy, N. (2008). Ink4a/Arf regulation by let-7b and Hmga2: A genetic pathway governing stem cell aging. Cell Stem Cell, 3(5), 469-470.
23. Li, O., Li, J., & Droge, P. (2007). DNA architectural factor and proto-oncogene HMGA2 regulates key developmental genes in pluripotent human embryonic stem cells. FEBS Letters, 581(18), 3533-3537.
24. Seiler, K., Soroush Noghabi, M., Karjalainen, K., Hummel, M., Melchers, F., & Tsuneto, M. (2011). Induced pluripotent stem cells expressing elevated levels of sox-2, oct-4, and klf-4 are severely reduced in their differentiation from mesodermal to hematopoietic progenitor cells. Stem Cells and Development, 20(7), 1131-1142.
25. Morshedi, A., Soroush Noghabi, M., & Dröge, P. (2011). Use of UTF1 genetic control elements as iPSC reporter. Stem Cell Reviews and Reports, doi: 10. 1007/s12015-011-9342-7.
26. Narita, M., Narita, M., Krizhanovsky, V., et al. (2006). A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell, 126(3), 503-514.
27. Cao, X., Clavijo, C., Li, X., et al. (2008). SUMOylation of HMGA2: Selective destabilization of promyelocytic leukemia protein via proteasome. Molecular Cancer Therapeutics, 7(4), 923-934.
28. Li, O., Vasudevan, D., Davey, C. A., & Droge, P. (2006). High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis, 44(11), 523-529.
29. Zhou, X., Benson, K. F., Ashar, H. R., & Chada, K. (1995). Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature, 376(6543), 771-774.
30. Fitzgerald, J., Rich, C., Zhou, F. H., & Hansen, U. (2008). Three novel collagen VI chains, alpha4(VI), alpha5(VI), and alpha6(VI). The Journal of Biological Chemistry, 283(29), 20170-20180.
31. Chen, D., Zhao, M., & Mundy, G. R. (2004). Bone morphogenetic proteins. Growth Factors, 22(4), 233-241.
32. Watanabe, S., Ueda, Y., Akaboshi, S., Hino, Y., Sekita, Y., & Nakao, M. (2009). HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. The American Journal of Pathology, 174(3), 854-868.
33. Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871-890.
34. Friedman, H. S., & Bigner, D. D. (2005). Glioblastoma multiforme and the epidermal growth factor receptor. The New England Journal of Medicine, 353(19), 1997-1999.
35. Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 7(3), 169-181.
36. Zhang, H., Berezov, A., Wang, Q., et al. (2007). ErbB receptors: From oncogenes to targeted cancer therapies. The Journal of Clinical Investigation, 117(8), 2051-2058.
37. Monzen, K., Ito, Y., Naito, A. T., et al. (2008). A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nature Cell Biology, 10(5), 567-574.
38. Nishino, J., Kim, I., Chada, K., & Morrison, S. J. (2008). Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell, 135(2), 227-239.
39. Ohshige, T., Iwata, M., Omori, S., et al. (2011). Association of new loci identified in European genome-wide association studies with susceptibility to type 2 diabetes in the Japanese. PLoS One, 6(10), e26911.
40. Brants, J. R., Ayoubi, T. A., Chada, K., Marchal, K., van de Ven, W. J., & Petit, M. M. (2004). Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Letters, 569(1-3), 277-283.
41. Voight, B. F., Scott, L. J., Steinthorsdottir, V., et al. (2010). Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nature Genetics, 42(7), 579-589.
42. Zhu, H., Shyh-Chang, N., Segre, A. V., et al. (2011). The Lin28/let-7 axis regulates glucose metabolism. Cell, 147(1), 81-94.
43. Firth, S. M., & Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews, 23(6), 824-854.
44. Arlotta, P., Tai, A. K.-F., Manfioletti, G., Clifford, C., Jay, G., & Ono, S. J. (2000). Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. Journal of Biological Chemistry, 275(19), 14394-14400.
45. Winter, N., Nimzyk, R., Bosche, C., Meyer, A., & Bullerdiek, J. (2011). Chromatin immunoprecipitation to analyze DNA binding sites of HMGA2. PLoS One, 6(4), e18837.